Core Viewpoint - Junshi Biosciences (01877) announced that its controlling shareholder and chairman, Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months starting from April 12, 2025, with a minimum of RMB 50 million allocated for A-shares [1] Group 1 - Mr. Xiong Jun intends to acquire shares through the Shanghai Stock Exchange and Hong Kong Stock Exchange, utilizing methods such as centralized bidding and block trading [1] - As of October 11, 2025, the share acquisition plan is more than halfway through, but Mr. Xiong has not yet made any purchases due to factors such as reporting periods, equity incentive matters, and funding arrangements [1] - The acquisition plan remains unfulfilled, and Mr. Xiong will continue to seek opportunities to increase his stake during the implementation period [1]

Core Viewpoint - The chairman of Junshi Biosciences, Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months, starting from April 12, 2025, with a minimum of RMB 50 million allocated for A-shares [1] Group 1 - Mr. Xiong Jun has not yet executed the share purchase plan due to various factors including reporting periods, equity incentive matters, and funding arrangements [1] - The share purchase plan is still ongoing, and Mr. Xiong intends to proceed with the acquisition of shares during the implementation period [1] - The plan may face risks due to changes in capital market conditions or other unpredictable factors that could hinder the expected outcomes of the share purchase [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海 君實生物醫藥科技股份有限公司關於控股股東、實際控制人之一兼董事長增持股 份進展暨增持時間過半公告》，僅供參閱。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年10月10日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 本公司董事会、全体董事及相关股东保证本公告 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-061 上海君实生物医药科技股份有限公司 关于控股股东、实际控制人之一兼董事长 增持股份进展暨增持时间过半公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： | 增持主体名称 | 熊俊 | | | | --- | --- | --- | --- | | 增持主体身份 | 控股股东、实控人 | 是 | 否 | | | 控股股东、实控人的一致行动人 | 是 | 否 | | | 直接持股 5%以上股东 | 是 | 否 | | | 董事、监事和高级管理人员 | 是 | 否 | | | 其他：__________ | | | 一、增持主体的基本情况 | 增持前持股比例 | | | --- | --- | | 增持前持股数量 （占总股本） | 87,856,618 股 8.56% | 注 1：熊俊先生直接持有公司股份 87,856,618 股（包含 87,854,018 股 A 股和 2,600 股 H 股，其中由 HK ...

Core Viewpoint - The recent criminal judgment in the commercial secret infringement case between Kobot and Saipu marks a significant breakthrough in the protection of intellectual property rights in China's high-end filtration membrane sector, which has been dominated by foreign companies for a long time [1][2]. Group 1: Case Details - Kobot, a domestic representative in the filtration membrane industry, won a lawsuit against Saipu for infringing on its commercial secrets, resulting in criminal penalties for Saipu's legal representative and former Kobot employees involved [1][2]. - The court sentenced individuals involved to prison terms ranging from one year and eleven months to two years and nine months, along with a total fine and compensation of 14.5 million yuan [1]. - This case reflects the internal competition and challenges faced by domestic companies in the high-tech sector, emphasizing the need for robust intellectual property protection to ensure that R&D investments translate into market competitiveness [2][3]. Group 2: Industry Context - The filtration membrane market is highly concentrated globally, with major players including Cytiva and Merck dominating the sector, while domestic companies like Kobot are striving to catch up [7]. - In 2023, China's production of virus removal filters reached 0.30 million units, marking a 55.7% increase, driven by local companies' efforts to scale up production [7]. - Kobot's products cover over 90% of domestic microelectronics and large pharmaceutical enterprises, with exports to over 100 countries, indicating its significant market presence [7]. Group 3: Implications for the Industry - The criminal judgment sends a strong signal against technology theft and is expected to deter similar unfair competition practices, particularly among smaller firms that rely on rapid expansion through talent poaching [5][6]. - The case is likely to prompt upstream and downstream companies in the industry to reassess their partners' compliance with intellectual property regulations, leading to a preference for domestic firms with clear technology sources and strict compliance management [6]. - The ongoing strengthening of intellectual property protection in China is anticipated to enhance domestic companies' willingness to invest in innovation, moving the industry from low-end substitution to high-end breakthroughs [8].

Market Performance - The Hong Kong stock market continued its decline, with notable drops in several biotech companies [1] - Innovent Biologics (09969) fell by 11.19%, closing at 14.760, with a market capitalization of 26.021 billion and a year-to-date increase of 141.18% [2] - Rongchang Biologics (09995) decreased by 10.22%, with a latest price of 95.350 and a total market value of 53.74 billion, reflecting a year-to-date increase of 562.15% [2] - WuXi AppTec (02268) and WuXi Biologics (02269) experienced declines of 5.68% and 5.32%, respectively, with market caps of 89.818 billion and 1585.28 billion [2] - Other companies such as Fuhong Hanlin (02696) and Kelun-Biotech (06990) also saw declines of over 4% [1][2] Company Highlights - Innovent Biologics has shown a significant year-to-date performance increase of 141.18% despite the recent drop [2] - Rongchang Biologics has the highest year-to-date increase among the listed companies at 562.15% [2] - WuXi Biologics and WuXi AppTec have maintained strong year-to-date increases of 120.84% and 138.50%, respectively [2] - Fuhong Hanlin and Kelun-Biotech also reported substantial year-to-date increases of 205.49% and 199.33% [2]

Core Viewpoint - The Hong Kong biopharmaceutical stocks continued to decline, with significant drops in several key companies, indicating a bearish trend in the sector [1]. Group 1: Stock Performance - Innovent Biologics (09969) experienced a decline of 11.19%, with a latest price of 14.760 and a total market capitalization of 26.021 billion, despite a year-to-date increase of 141.18% [2]. - Rongchang Biologics (09995) fell by 10.22%, with a latest price of 95.350 and a market cap of 53.747 billion, showing a remarkable year-to-date increase of 562.15% [2]. - WuXi AppTec (02268) saw a decrease of 5.68%, with a latest price of 73.100 and a market cap of 89.818 billion, maintaining a year-to-date increase of 138.50% [2]. - WuXi Biologics (02269) dropped by 5.32%, with a latest price of 38.780 and a market cap of 158.528 billion, reflecting a year-to-date increase of 120.84% [2]. - Fuhong Hanlin (02696) declined by 4.42%, with a latest price of 72.400 and a market cap of 39.349 billion, showing a year-to-date increase of 205.49% [2]. - Kelun-Biotech (06990) decreased by 4.25%, with a latest price of 488.800 and a market cap of 113.981 billion, with a year-to-date increase of 199.33% [2]. - WuXi AppTec (02359) fell by 4.19%, with a latest price of 114.400 and a market cap of 339.275 billion, reflecting a year-to-date increase of 109.21% [2]. - Gendicine (09688) saw a decrease of 2.83%, with a latest price of 25.440 and a market cap of 28.432 billion, with a year-to-date increase of 21.72% [2]. - CanSino Biologics (09926) declined by 2.05%, with a latest price of 128.800 and a market cap of 118.643 billion, reflecting a year-to-date increase of 112.19% [2]. - Junshi Biosciences (01877) fell by 2.02%, with a latest price of 29.100 and a market cap of 29.877 billion, showing a year-to-date increase of 151.30% [2].

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Junshi Biosciences, indicating a significant level of financing and margin trading activity, suggesting investor interest and potential volatility in the stock [1][2][3] Group 2 - As of October 9, Junshi Biosciences experienced a trading decline of 0.96% with a transaction volume of 488 million yuan, and a net financing purchase of 11.61 million yuan [1] - The total financing and margin trading balance for Junshi Biosciences reached 1.4 billion yuan, with the financing balance accounting for 4.43% of the circulating market value, indicating a high level of leverage compared to the past year [1] - The company reported a revenue of 1.168 billion yuan for the first half of 2025, reflecting a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a 36.01% increase in losses compared to the previous period [2]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a rebound, with significant gains in various pharmaceutical stocks, indicating strong buying interest in the market [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect innovative drug ETF (520880) opened lower but quickly turned positive, reaching nearly a 1% increase, reflecting strong buying momentum [1]. - Over the past 20 trading days, the ETF has seen net inflows exceeding 675 million yuan, with 15 out of those days recording inflows [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index has shown a year-to-date increase of 108.14%, outperforming other innovative drug indices [4][5]. Group 2: Industry Catalysts - Upcoming industry conferences, such as ESMO in October and ASH in December, are expected to serve as catalysts for the innovative drug sector [3]. - There has been notable progress in external licensing transactions for innovative drugs, with several significant deals anticipated, indicating potential for domestic innovative drugs to enter international markets [3]. - The fourth quarter will see the implementation of domestic policy changes, including adjustments to the medical insurance catalog, which may further support the sector [3]. Group 3: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) exclusively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, focusing solely on innovative drug development companies [3][4]. - The ETF is the first of its kind in the market, with a fund size of 1.806 billion yuan and an average daily trading volume of 493 million yuan since its inception, making it the largest and most liquid ETF in its category [5].

Core Insights - BeiGene is positioned as a leading innovative pharmaceutical company in China, aiming to achieve profitability by 2025, marking a transition from R&D investment to commercialization [1] - The company is expanding its product pipeline into solid tumors and immunology, leveraging new technology platforms such as ADC and PROTAC [1] Global R&D and Commercialization - BeiGene has established a global clinical and commercialization system with a team of approximately 3,700, enabling clinical trials with minimal reliance on CROs [1] - Key products, Baiyueze and Baizean, have been approved in 75 and 47 markets respectively, covering hematological malignancies, solid tumors, and immune diseases, showcasing strong market penetration and product diversity [1] - In the first half of 2025, the company's product revenue reached $2.41 billion, a year-on-year increase of 44.5%, with Q2 revenue of $1.3 billion, up 41.4% [1] Hematological Malignancies - The core product, Zebutinib, saw significant sales growth, reaching $1.74 billion in the first half of 2025, a 55% increase year-on-year [2] - In the U.S., Baiyueze sales in Q2 2025 were $684 million, up 43%, while in Europe, sales were $150 million, reflecting an 85% increase [2] - The company is advancing its pipeline with Sonrotoclax expected to report data in H2 2025 and BTK CDAC (16673) recognized by the FDA for its innovative approach to BTKi resistance [2] Solid Tumors - BeiGene is focusing on next-generation solid tumor drugs based on PD-1 monoclonal antibodies, particularly in breast, lung, and gastric cancers [3] - In breast cancer, the company is developing CDK4 and CDK2 series products, with CDK4i expected to enter Phase 3 trials in 2026 [3] - In lung cancer, the combination of PRMT5i and MATA2i is set to complete patient enrollment in H2 2025, while several other candidates are in early-stage trials [3] Immunology and Inflammation - The IRAK4 CDAC is currently in Phase 2 trials for atopic dermatitis and nodular prurigo, with data expected in H2 2025 [3] - The company reported a GAAP gross margin of 87.4% in Q2 2025, a 2.4 percentage point increase year-on-year, with a net profit of $94 million and adjusted net profit of $253 million, indicating enhanced profitability [3] Revenue Forecast and Investment Recommendations - Revenue projections for Baiyueze from 2025 to 2027 are $27.96 billion, $35.60 billion, and $41.68 billion, with year-on-year growth rates of 49%, 27%, and 17% respectively [4] - Bai Zean's revenue is expected to be $750 million, $880 million, and $1.02 billion for the same period, with growth rates of 20%, 18%, and 16% [4] - The overall revenue forecast for BeiGene from 2025 to 2027 is $37.66 billion, $47.49 billion, and $55.85 billion, with growth rates of 38%, 26%, and 18% [4] - The company is valued at a significantly lower price-to-sales ratio compared to comparable companies, highlighting its investment attractiveness [4]